VMD at a glance
VIEMED HEALTHCARE, INC. (VMD, SEC CIK 1729149) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as August 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), VIEMED HEALTHCARE, INC. (VMD) reported revenue of $270.3 million (up 20.5% from FY2024) and net income of $14.9 million. Diluted EPS was $0.37.
- As of September 30, 2026, 24 institutional investment managers tracked by SignalX reported holding VIEMED HEALTHCARE, INC. (VMD) shares worth $111.9 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $270.3M
- +20.5% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 24 funds
- $111.9M · −1 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material risk-factor changes from the December 31, 2025 Form 10-K
- Carried-forward business, financial-condition, and future-results risks remain applicable
Management Discussion & Analysis
- Revenue $80.7M, up 12.2% YoY from $71.9M, driven by sleep therapy, respiratory care and women’s health
- Net income margin 5.9% vs 5.0% YoY, operating margin 8.6% vs 7.8%
- Best segment: equipment and supply sales $19.4M, up 23.7%; worst: ventilator rentals $37.5M, up 7.4%
- Cash $9.7M at September 30 vs $13.5M at December 31; nine-month operating cash flow $35.5M
- Capital deployment: $23.8M equipment purchases, $7.7M share repurchases, $7.6M term-loan payments
- Headwinds: reimbursement pressure, CMS coverage criteria, potential future tariffs and competitive bidding changes
AI summary of the VMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 and nine-month fiscal 2026 results announced for periods ended September 30, 2026
- Financial Supplement provides additional operating and financial detail for investor analysis
Item 7.01: Regulation FD Disclosure
- Investor deck published as Exhibit 99.3 and available on Viemed’s investor website
- Presentation intended for investor and analyst meetings, signaling updated corporate messaging
Item EX-99.3: Item EX-99.3
- 2026 guidance: net revenue $316M-$320M and Adjusted EBITDA $64M-$66M, signaling continued double-digit growth
- Q3 2026 revenue $80.7M, up 12% YoY, with ventilator rental revenue up 7.4% to $37.5M
Item EX-99.2: Item EX-99.2
- Record Q3 revenue $80.7M, up 12.2% YoY and 3.3% sequentially, confirming continued platform expansion
- Net income $4.6M, up 32.0% YoY, with diluted EPS $0.11 and margin improving to 5.7%
Item EX-99.1: Item EX-99.1
- Q3 revenue reached a record $80.7M, up 12.2% year over year and 3.3% sequentially, confirming diversified growth momentum
- Net income attributable to Viemed rose 32.0% year over year to $4.6M, while diluted EPS increased to $0.11
Item 7.01: Regulation FD Disclosure
- Investor presentation released under Regulation FD, intended for discussions with investors and analysts
- Exhibit 99.1 contains the substantive company updates and operating information
Item EX-99.2: Item EX-99.2
- Q2 revenue reached a record $78.1M, up 24% year over year and 4% sequentially, supporting stronger full-year growth expectations
- Full-year 2026 revenue guidance increased to $314M-$320M from $312M-$320M
Item EX-99.1: Item EX-99.1
- Q2 revenue $78.1M, up 23.9% YoY and 3.6% sequentially, marking a company record
- Net income attributable to Viemed $2.8M, or $0.07 diluted EPS, while Adjusted EBITDA declined 4.0% to $13.7M
Item 2.02: Results of Operations and Financial Condition
- Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
- Press release and financial supplement available as Exhibits 99.1 and 99.2
AI summaries of VMD 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for VMD
Don't miss the next VMD filing
- Alerts as it files. A push when VMD files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut VMD, by share count.
- Ask anything. An AI agent that reads every VMD filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Smokoff Timothy | D | Aug 19, 2026 | 3,757 | $8.94 |
| Heltz Sabrina | M | Aug 19, 2026 | 3,757 | - |
| Smokoff Timothy | M | Aug 19, 2026 | 15,029 | - |
| Smokoff Timothy | M | Aug 19, 2026 | 3,757 | - |
| Kaushal Nitin | M | Aug 19, 2026 | 18,786 | - |
| Heltz Sabrina | M | Aug 19, 2026 | 15,029 | - |
| Heltz Sabrina | M | Aug 19, 2026 | 15,029 | - |
| Heltz Sabrina | D | Aug 19, 2026 | 3,757 | $8.94 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $224.3M | $270.3M |
| Gross Profit | - | $133.2M | $155.5M |
| Operating Income | - | $17.9M | $22.9M |
| Net Income | - | $11.3M | $14.9M |
| Gross Margin | - | 59.4% | 57.5% |
| Op. Margin | - | 8.0% | 8.5% |
| Net Margin | - | 5.0% | 5.5% |
| Balance Sheet | |||
| Total Assets | $154.9M | $177.1M | $199.2M |
| Equity | $113.9M | $131.4M | $141.5M |
| ROE | - | 8.6% | 10.6% |
| Per Share | |||
| EPS | - | $0.28 | $0.37 |
| Cash Flow | |||
| Operating CF | - | $39.1M | $51.9M |
| CapEx | - | $37.8M | $40.0M |
Source: XBRL data in VIEMED HEALTHCARE, INC. (VMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate VMD share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 24 | $111.9M |
| Q2 2026 | 25 | $137.7M |
| Q1 2026 | 25 | $105.4M |
| Q4 2025 | 23 | $84.6M |
| Q3 2025 | 22 | $74.0M |
| Q2 2025 | 22 | $69.8M |
| Q1 2025 | 21 | $36.4M |
| Q4 2024 | 15 | $29.8M |
- Ameriprise Financial+294.7K (+29%)
- Millennium Management+220.2K (+424%)
- AQR Capital Management+187.7K (+91%)
- BlackRock+154.3K (+3%)
- Vanguard Portfolio Management LLC+142.3K (+51%)
- Goldman Sachs Group−643.6K (-53%)
- Bank of America Corp−101.9K (-64%)
- JPMorgan Chase & Co−93.1K (-84%)
- Citadel Advisors LLC−75.9K (-32%)
- Morgan Stanley−30.6K (-10%)
- StoneX Group Inc.+18.5K
- FMR LLC (Fidelity)−11.2K
- Prudential Financial−11.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 177 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
VMD filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 8-K | Aug 20, 2026 | - | Analysis | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 4 | Aug 19, 2026 | - | - | - |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jun 26, 2026 | - | - | - |
| 4 | Jun 26, 2026 | - | - | - |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 4 | Mar 20, 2026 | - | - | - |
| 8-K | Mar 16, 2026 | - | Analysis | - |
| 10-K | Mar 4, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 4, 2026 | - | Analysis | - |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - | |
| 4 | Feb 2, 2026 | - | - |
Related Health Care companies
- AGL · agilon health, inc.Services-Misc Health & Allied Services, NEC
- DVA · DaVitaServices-Misc Health & Allied Services, NEC
- PGNY · Progyny, Inc.Services-Misc Health & Allied Services, NEC
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
VMD SEC filings: frequently asked questions
Which institutions hold VMD stock?
As of September 30, 2026, the largest VIEMED HEALTHCARE, INC. (VMD) holders among the 13F filers tracked by SignalX were BlackRock ($45.0 million), Vanguard Capital Management LLC ($12.0 million), Ameriprise Financial ($11.8 million), State Street Corp ($6.9 million), Two Sigma Investments ($5.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was VMD's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), VIEMED HEALTHCARE, INC. (VMD) reported revenue of $270.3 million (up 20.5% from FY2024) and net income of $14.9 million. Diluted EPS was $0.37. The figures come from the XBRL data in the 10-K.
What did VMD report in its latest 8-K?
VIEMED HEALTHCARE, INC. (VMD) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 and nine-month fiscal 2026 results announced for periods ended September 30, 2026.
What are the latest VMD SEC filings?
VIEMED HEALTHCARE, INC. (VMD) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on August 19, 2026.
What is VMD's SEC CIK number?
VIEMED HEALTHCARE, INC. (VMD)'s SEC Central Index Key (CIK) is 1729149. EDGAR lists every VMD filing under that number.
Ask anything about VMD
The research agent reads VMD's filings, financials, insider trades and 13F holders, then answers with sources.